User:Mr. Ibrahem/Idelalisib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Idelalisib
Idelalisib structure
Clinical data
Pronunciation/aɪˈdɛləlɪsɪb/
eye-DEL-ə-li-sib
Trade namesZydelig
Other namesGS-1101, CAL-101
AHFS/Drugs.comMonograph
MedlinePlusa614040
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth (tablets)
Drug classPhosphoinositide 3-kinase inhibitor[1]
Legal status
Legal status
  • US: ℞-only
  • EU: Rx-only[2]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding>84%[3]
MetabolismAldehyde oxidase (~70%), CYP3A4 (~30%);[4] UGT1A4 (minor)
MetabolitesGS-563117 (inactive in vitro)
Onset of actionTmax = 1.5 hours
Elimination half-life8.2 hours
ExcretionFeces (78%), urine (14%)
Identifiers
  • 5-Fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone
Chemical and physical data
FormulaC22H18FN7O
Molar mass415.432 g·mol−1
3D model (JSmol)
  • CC[C@H](Nc1ncnc2nc[nH]c12)c4nc3cccc(F)c3c(=O)n4c5ccccc5
  • InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
  • Key:IFSDAJWBUCMOAH-HNNXBMFYSA-N

Idelalisib, sold under the brand name Zydelig, is a medication used to treat chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma (SLL).[3][2] It is used when other treatments have failed or are not appropriate.[3][5] It is taken by mouth.[3]

Common side effects include infection, low white blood cells, diarrhea, liver problems, rash, and fever.[2] Other side effects may include allergic reactions.[3] Use in pregnancy may harm the baby.[3] It is a phosphoinositide 3-kinase inhibitor which blocks PI3Kδ.[1][2]

Idelalisib was approved for medical use in the United States and Europe in 2014.[1][2] In the United Kingdom a month of treatment costs the NHS about £3,100 as of 2021.[5] This amount in the United States costs about 12,300 USD.[6]

References[edit]

  1. ^ a b c "Idelalisib Monograph for Professionals". Drugs.com. Archived from the original on 24 October 2020. Retrieved 25 November 2021.
  2. ^ a b c d e f g "Zydelig EPAR". European Medicines Agency (EMA). Archived from the original on 23 October 2020. Retrieved 21 October 2020.
  3. ^ a b c d e f g h "Zydelig- idelalisib tablet, film coated". DailyMed. 22 October 2018. Archived from the original on 23 October 2020. Retrieved 21 October 2020.
  4. ^ "Clinical Pharmacology and Biopharmaceutics Review: Zydelig (idelalisib)" (PDF). U.S. Food and Drug Administration. p. 6. Archived (PDF) from the original on 28 April 2016. Retrieved 15 April 2016.
  5. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1029. ISBN 978-0857114105.
  6. ^ "Zydelig Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 April 2021. Retrieved 25 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Idelalisib&oldid=1220659497"